Tag: Erytech
Pherecydes Pharma carries out a capital increase and merges with Erytech Pharma – 02/20/2023 at 09:50
(AOF) – Pherecydes Pharma, a biotechnology company specializing in precision phage therapy intended to treat antibiotic-resistant and/or complicated bacterial infections, today announces the completion of the capital increase announced on…
ERYTECH and PHERECYDES announce a strategic merger project with a view to creating a world leader in phage therapy – 02/15/2023 at 22:30
Lyon and Nantes (France), February 15, 2023 – 10:30 p.m. CET – ERYTECH Pharma (“ERYTECH”; Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in…
PHERECYDES: planned strategic merger with Erytech with a view to creating a world leader in phage therapy – 02/15/2023 at 23:00
– The strategic merger would rely on the expertise and complementary resources of the two companies in order to accelerate the development of phage therapy intended to fight against antibiotic…
Erytech: BVF Partners drops below 10% – 12/29/2022 at 1:38 pm
(CercleFinance.com) – BVF Partners LP, acting on behalf of the funds it manages, declared to the AMF that it crossed downwards, on December 23, the thresholds of 10% of the…
Erytech Pharma: BVF Partners LP under 10% of the capital – 2022/12/29 at 15:25
(AOF) – In a letter received on December 29, 2022, the company BVF Partners LP, acting on behalf of the funds it manages, declared to the AMF that it had…
Erytech: As of September 30, cash and cash equivalents amounted to €47.3 million
(Boursier.com) — The net loss for the first months of 2022 at Erytech amounted to 6.2 million euros, an improvement of35.4 million euros compared to the previous year, resulting from…
ERYTECH takes stock of its activities and publishes its 2022 half-year results – 09/12/2022 at 22:05
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected] Conference call and webcast: Tuesday,…
Erytech pharma: The biotech Erytech gives up its treatment against leukemia and falls on the stock market
(BFM Bourse) – The Lyon-based company has decided to no longer seek approval from the US health authority for a potential treatment for acute lymphoblastic leukemia. The company is weighing…
ERYTECH provides an update on its regulatory activity – 08/24/2022 at 22:05
ERYTECH provides an update on its regulatory activity Cessation of activities in view of submitting an application for approval of Graspa® in the treatment of patients with Acute Lymphoblastic Leukemia…
ERYTECH provides an update on its regulatory activity – 08/24/2022 at 22:05
ERYTECH provides an update on its regulatory activity Stop of the activities in view of submit a request of approval for grass ® in the treatment of patients with Acute…
Minutes – ERYTECH Combined General Meeting of June 24, 2022 – 06/24/2022 at 10:05 p.m.
MINUTES – GENERAL ASSEMBLY MIXED of ERYTECH DU 2 4 JUNE 2022 Lyon (France), and Cambridge, MA (US) the 24 June 2 022 – L’ HAS General meeting of ERYTECH…
Minutes – ERYTECH Combined General Meeting of June 24, 2022 – 06/24/2022 at 10:05 p.m.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected] Lyon (France), and Cambridge, MA…